PPARG and type 2 diabetes mellitus: For years now, the balance between the safety and efficacy of pioglitazone (Pio), a peroxisome proliferator-activated receptor gamma (PPAR γ) agonist, in the treatment of patients with type 2 diabetes (T2D) has been heavily debated.